A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Avadomide (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celgene Corporation
- 01 Nov 2017 Planned End Date changed from 1 Jul 2017 to 28 Dec 2018.
- 01 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2016 Planned primary completion date changed from 1 May 2016 to 1 Mar 2017.